IIIIIIII nevro 2Q 2021 Earnings Presentation August 4, 2021 Forward-looking Statements In addition to historical information, this presentation contains forward-looking statements reflecting the company's current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including: our third quarter financial guidance; our belief that there is a significant opportunity to offer our innovative therapy to PDN patients who are una ...

Nevro Corp. (NYSE:NVRO) Q2 2021 Earnings Conference Call August 4, 2021 4:30 PM ET Company Participants Julie Dewey – Vice President-Investor Relations and Corporate Communications Keith Grossman – Chairman, Chief Executive Officer and President Rod MacLeod – Chief Financial Officer Conference Call Participants Larry Biegelsen – Wells Fargo Bob Hopkins – Bank of America Robbie Marcus – JPMorgan Joanne Wuensch – Citi Matt Taylor – UBS Cecilia Furlong – Morgan Stanley Adam Maeder – Piper Sandler Chris Pasqual ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36715 Nevro Corp. (Exact name of registrant as specified in its charter) Delaware 56-2568057 (State or other jurisdiction of incorporation or organization) (I.R.S ...

Financial Data and Key Metrics Changes - Nevro reported Q1 2021 worldwide revenue of $88.6 million, a 1% increase compared to Q1 2020 and an 8% increase compared to Q1 2019 [6][25] - U.S. sales were $74.7 million, a decrease of 1% year-over-year but an increase of 14% compared to Q1 2019 [6] - International revenue increased 14% year-over-year to $13.9 million, with a 4% increase on a constant currency basis [6] - Gross profit for Q1 2021 was $62.3 million, a 3% increase compared to the prior year [25] - Net loss from operations was $22.5 million, a 2% improvement compared to a loss of $23.1 million in the prior year [28] Business Line Data and Key Metrics Changes - U.S. permanent implant procedures remained flat year-over-year, while trial procedures declined by 4% [7] - Approximately 134 scheduled U.S. permanent implant procedures were canceled due to COVID, with 60% still unrecovered by the end of the quarter [8] - The company reported a record number of new patient leads from direct marketing efforts, indicating potential future growth [7] Market Data and Key Metrics Changes - The impact of COVID-19 on revenue and procedures lessened as the quarter progressed, with March showing encouraging improvement [7] - The company expects the U.S. market to recover more rapidly than international markets [7] Company Strategy and Development Direction - Nevro aims to launch its PDN (painful diabetic neuropathy) therapy in the second half of 2021, with a focus on generating awareness and expanding market access [10][13] - The company introduced a new brand identity, HFX, to unify its product offerings and enhance patient support [17] - The recent Omnia upgrade, HFX Connect, is expected to improve patient care and operational efficiency [18][21] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the recovery from COVID-19 and the potential for increased patient demand for SCS therapy [9][23] - The company anticipates a gradual improvement in revenue and patient engagement as COVID-related restrictions ease [9][23] - Full-year 2021 revenue guidance was updated to approximately $440 million to $450 million, reflecting a 22% to 24% growth over the prior year [34] Other Important Information - Legal expenses related to patent litigation were $5.9 million for Q1 2021, significantly higher than the previous year [26] - The company published its first ESG report, highlighting its commitment to corporate responsibility [22] Q&A Session Summary Question: Current trialing perspective and Q2 guidance backlog conversion - Management noted that trialing improved in March, with expectations for continued improvement, but acknowledged that it is not yet at desired levels [42] Question: Size of the PDN sales force and payer coverage updates - The PDN sales force is expected to consist of 30 to 40 people, with ongoing efforts to engage payers for coverage decisions [44][48] Question: Percentage of payers expected to cover PDN by year-end - Management estimated that around 25% to 30% of total covered lives may have PDN coverage by the end of 2021, with expectations for growth in 2022 [51] Question: Omnia's market education and competitive positioning - Omnia currently accounts for 70% to 80% of total utilization, with management confident in its competitive advantages [54][56] Question: Guidance increase makeup - The guidance increase reflects optimism in core business recovery, market share capture, and contributions from PDN in the latter half of the year [58][60]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36715 Nevro Corp. (Exact name of registrant as specified in its charter) Delaware 56-2568057 (State or other jurisdiction of incorporation or organization) (I.R. ...

4Q and Full-Year 2020 Earnings Presentation 1 February 24, 2021 IIIIIIII neviro Forward-looking Statements | --- | --- | --- | --- | |------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

Nevro Corp (NYSE:NVRO) Q4 2020 Earnings Conference Call February 24, 2021 4:30 PM ET Company Participants Julie Dewey - VP, IR & Corporate Communications Keith Grossman - Chairman, CEO & President Roderick MacLeod - CFO Conference Call Participants Adam Maeder - Piper Sandler & Co. William Plovanic - Canaccord Genuity Robert Hopkins - Bank of America Merrill Lynch David Lewis - Morgan Stanley Allen Gong - JPMorgan Chase & Co. Danielle Antalffy - SVB Leerink Kaila Krum - Truist Securities Young Li - UBS Inve ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the year ended December 31, 2020 | Title of each class | Trading Symbol | Name of exchange on which registered | | --- | --- | --- | | Common Stock, par value $0.001 per share | NVRO | New York Stock Exchange | or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 001-36715 ...

Nevro Corp. (NYSE:NVRO) Q3 2020 Earnings Conference Call November 5, 2020 4:30 PM ET Company Participants Keith Grossman - Chairman, Chief Executive Officer & President Roderick MacLeod - Chief Financial Officer Conference Call Participants Lawrence Biegelsen - Wells Fargo Securities Robert Marcus - JPMorgan Chase & Co. David Lewis - Morgan Stanley Robert Hopkins - Bank of America Merrill Lynch Danielle Antalffy - SVB Leerink Joanne Wuensch - Citigroup Kaila Krum - Truist Securities Margaret Kaczor - Willia ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36715 Nevro Corp. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 56-2568057 ( ...